about
The Vaccine Safety Datalink: a model for monitoring immunization safetyMeasles-mumps-rubella-varicella combination vaccine and the risk of febrile seizuresIdentifying birth defects in automated data sources in the Vaccine Safety DatalinkImmediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.Influenza Vaccination During Pregnancy: Influenza Seasons 2002-2012, Vaccine Safety Datalink.Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination.Safety of quadrivalent human papillomavirus vaccine administered routinely to females.An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.Safety of measles-containing vaccines in 1-year-old children.Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013.Kaiser Permanente Vaccine Study Center: Highlights of 2009-2012.Attitudes and beliefs of parents concerned about vaccines: impact of timing of immunization information.Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children.Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy.Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Licensed pertussis vaccines in the United States. History and current state.Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies.Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age.Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink.Biologically plausible and evidence-based risk intervals in immunization safety research.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Geographic clusters in underimmunization and vaccine refusal.Kaiser Permanente Northern California pregnancy database: Description and proof of concept study.Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers.Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine.Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults.Waning Tdap Effectiveness in Adolescents.Effectiveness of pertussis vaccines for adolescents and adults: case-control study.Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.Varicella vaccination and ischemic stroke in children: is there an association?Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy.Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis.First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring.Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder.
P50
Q27010367-BB9BF8F3-6AC6-4C4B-B5DC-5571ECDF37CCQ28286437-236FCBA3-5869-4191-9EED-ED4DFC428FA2Q28595391-05C0C62B-760D-4991-9FD7-08A83FC82940Q30354452-90728D4F-AD02-4F6F-97C0-10D21DE05809Q30380970-BD61151F-E23C-4507-9215-367C0CD22325Q30426121-114C7C05-8C69-41BB-BD19-88E7FFBD7A90Q33161840-25E96FAF-C83A-4BA4-A0D6-DFEFD8732DAFQ33165899-13980D8B-C5E7-4AD7-BB8A-21ED152350CBQ33419617-DB8BA13F-3DA9-464F-83B7-581456D1F483Q33429175-1A99B283-C9DE-4511-A38E-D890C057BBE6Q35890630-359F2E26-D5E3-4485-A379-58D31C1A0165Q35953676-B434EE99-B0CB-47B3-AC0A-D2897B73FB38Q36201344-8756BCD6-11B0-41B3-B744-67957050268FQ36201827-3DDACE22-5720-449F-B718-B7F75E72173AQ36457330-CB1FF855-FFAE-43FA-BE19-CD7138996097Q36882923-AB175063-C033-42FC-890C-868375D26568Q37154787-1A7EE0B8-F699-4363-A8FF-2944B31FFB75Q37316006-92972DCD-F76A-4189-8EC7-F552555D0667Q37629055-7A1CD8FA-B339-4251-A91E-D39015690987Q37866538-E8FBCF4E-87F6-47C9-A028-65AD18594B6FQ37901734-22A829B7-3F8F-4321-82E9-6C4CB931081EQ37908267-EF09BEC7-6F8D-486E-904A-C9EFF12CFF63Q37910447-A92CA855-1CA8-4A2F-8140-D28FBDDF2D4CQ38029858-5E44A29D-799B-4A80-A0BC-9A59DC3C4A53Q38045920-18FB7BB9-415C-44B4-8F5F-3117E076AF52Q38051944-502A1515-88B4-4954-94AC-622E36ABE60EQ38324582-118B26D5-915B-4A7C-BD39-B4347751DC0DQ38386015-28775673-8E89-46D8-813D-639E00510417Q38390602-0F206062-413C-4C7C-AC8E-7F2C4AC912CEQ38400982-50A9ACEF-4CFF-49C4-BAFC-D88A882D46EBQ38406816-90715269-F05A-4FD8-BAC5-E7B9D5B4CC42Q38409558-545D1593-0F35-4310-AC38-FC41DE1120DEQ38425355-67138EB1-1377-425F-9EB1-F567E5F8FDDCQ38426254-F9920E89-FA0E-4788-9404-555FAA0E6F2EQ38452181-6514EDB3-81D4-432A-88DA-433C49AF1596Q38498875-79325731-76DB-41A5-8299-BD0AC01A7B11Q38630488-74D32420-CC2E-4154-9A56-173CD322FEB9Q38756466-2F566173-358D-49A4-8C42-F3198CD0AAFBQ38760334-BFA34C72-CB54-4EB9-98ED-6648E35BE247Q39148321-14171538-A11B-4554-997D-786616ED09B5
P50
name
Nicola P Klein
@ast
Nicola P Klein
@en
Nicola P Klein
@nl
type
label
Nicola P Klein
@ast
Nicola P Klein
@en
Nicola P Klein
@nl
prefLabel
Nicola P Klein
@ast
Nicola P Klein
@en
Nicola P Klein
@nl